INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) financials

INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1988 as a JV between Apollo Hospitals Enterprise Ltd. (AHEL) and the Delhi Government, Indraprastha Medical Corporation Ltd. is a super speciality tertiary care hospital in New Delhi. The Co. currently has 52 speciality departments.[1]

Market Cap: ₹2,934Cr.
Current Price: ₹320
Stock P/E: 15.6
ROE: 27.4%
ROCE: 35.8%
Book Value: ₹80.8
Dividend Yield: 1.25%
52W High / Low: ₹641/317

In Jun 2026, INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) reported sales ₹406 Cr and net profit ₹56 Cr.

Annual TTM: sales ₹1,524 Cr, net profit ₹188 Cr.

Shareholding: Promoters 51.00% (Sep 2026), FIIs 2.39% (Sep 2026), DIIs 1.77% (Sep 2026), Public 44.83% (Sep 2026), No. of Shareholders 77,706% (Sep 2026).

INDRAMEDCO quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	350	325	334	365	381	372	365	406
Expenses	286	273	272	292	310	310	304	326
Operating Profit	64	52	61	73	71	62	61	80
OPM %	18%	16%	18%	20%	19%	17%	17%	20%
Other Income	6	5	6	7	7	7	7	8
Interest	2	2	1	2	2	1	1	2
Depreciation	11	11	11	10	11	11	11	12
Profit before tax	57	45	55	68	66	56	55	75
Tax %	26%	26%	26%	25%	25%	27%	24%	25%
Net Profit	42	33	41	51	49	41	42	56
EPS in Rs	4.63	3.58	4.47	5.61	5.40	4.47	4.55	6.09
Raw PDF	—	—	—	—	—	—	—	—

INDRAMEDCO profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	831	613	888	1,099	1,245	1,356	1,483	1,524
Expenses	743	572	768	947	1,050	1,112	1,215	1,250
Operating Profit	87	41	120	152	195	245	267	274
OPM %	11%	7%	14%	14%	16%	18%	18%	18%
Other Income	-0	-0	-3	9	16	22	28	30
Interest	6	3	3	4	4	6	6	6
Depreciation	33	33	35	39	40	44	44	45
Profit before tax	48	4	79	117	166	216	246	253
Tax %	9%	46%	26%	26%	25%	26%	25%	—
Net Profit	44	2	59	86	124	161	184	188
EPS in Rs	4.76	0.25	6.39	9.40	13.52	17.56	20.03	20.51
Dividend Payout %	0%	0%	39%	32%	33%	26%	20%	—

INDRAMEDCO balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	92	92	92	92	92	92	92	92
Reserves	152	176	181	234	288	386	505	649
Borrowings	21	4	3	5	2	34	33	37
Other Liabilities	157	177	157	131	173	212	222	214
Total Liabilities	422	449	432	462	555	723	852	991
Fixed Assets	280	303	283	277	275	347	328	365
CWIP	1	0	3	0	3	0	33	3
Investments	0	0	0	0	0	0	0	0
Other Assets	141	146	145	185	278	376	491	624
Total Assets	422	449	432	462	555	723	852	991

INDRAMEDCO cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	75	86	27	94	144	200	157	167
Cash from Investing Activity	-17	-40	-19	-74	-108	-158	-111	-178
Cash from Financing Activity	-44	-43	-3	-3	-26	-32	-46	-46
Net Cash Flow	14	4	5	17	11	9	-0	-57
Free Cash Flow	58	46	6	65	100	131	120	108
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	110%	113%	88%	95%	102%	127%	89%	88%

INDRAMEDCO shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%
FIIs	2.88%	2.94%	2.73%	2.41%	2.72%	2.43%	2.77%	2.39%
DIIs	3.18%	3.56%	3.56%	3.51%	0.82%	0.87%	0.59%	1.77%
Public	42.91%	42.50%	42.74%	43.08%	45.43%	45.69%	45.65%	44.83%
No. of Shareholders	69,697	70,491	70,211	70,914	71,225	72,980	75,098	77,706

INDRAMEDCO key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	35	35	40	18	23	17	20	28
Inventory Days	—	—	—	—	—	—	—	—
Days Payable	—	—	—	—	—	—	—	—
Cash Conversion Cycle	35	35	40	18	23	17	20	28
Working Capital Days	-5	-10	-1	-2	-12	-24	-19	-4
ROCE %	19%	21%	3%	29%	34%	38%	39%	36%

INDRAMEDCOUpdated 18 Oct 2026, 2:57

Indraprastha Medical Corp

INDRAMEDCOUpdated 18 Oct 2026, 2:57

Market Cap

₹2,934Cr.

Current Price

₹320

High / Low

₹641/317

Stock P/E

15.6

ROE27.4%

ROCE35.8%

Book Value₹80.8

Face Value₹10.0

Dividend Yield1.25%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	307	1	259	4	10	40	24	30	3.33
Sep 2023	317	1	267	4	10	44	25	33	3.58
Dec 2023	306	1	259	4	10	41	28	29	3.21
Mar 2024	315	2	266	5	10	42	25	31	3.4
Jun 2024	348	2	281	5	11	60	25	45	4.88
Sep 2024	350	2	286	6	11	57	26	42	4.63
Dec 2024	325	2	273	5	11	45	26	33	3.58
Mar 2025	334	1	272	6	11	55	26	41	4.47
Jun 2025	365	2	292	7	10	68	25	51	5.61
Sep 2025	381	2	310	7	11	66	25	49	5.4
Dec 2025	372	1	310	7	11	56	27	41	4.47
Mar 2026	365	1	304	7	11	55	24	42	4.55
Jun 2026	406	2	326	8	12	75	25	56	6.09

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	714	8	630	1	28	50	34	32	3.54
Mar 2016	755	7	675	1	35	39	37	24	2.66
Mar 2017	766	8	686	0	31	41	36	26	2.86
Mar 2018	753	9	678	-1	31	34	38	21	2.3
Mar 2019	788	7	706	-1	30	45	36	28	3.1
Mar 2020	831	6	743	0	33	48	9	44	4.76
Mar 2021	613	3	572	0	33	4	46	2	0.25
Mar 2022	888	3	768	-3	35	79	26	59	6.39
Mar 2023	1099	4	947	9	39	117	26	86	9.4
Mar 2024	1245	4	1050	16	40	166	25	124	13.52
Mar 2025	1356	6	1112	22	44	216	26	161	17.56
Mar 2026	1483	6	1215	28	44	246	25	184	20.03
TTM	1524	6	1250	30	45	253	—	188	20.51

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	51%
FIIs	2.39%
DIIs	1.77%
Public	44.83%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	51%	0.95%	6.36%	41.69%
Mar 2024	51%	1.08%	4.91%	43.01%
Jun 2024	51%	1.7%	3.14%	44.14%
Sep 2024	51%	2.64%	3.19%	43.16%
Dec 2024	51%	2.88%	3.18%	42.91%
Mar 2025	51%	2.94%	3.56%	42.5%
Jun 2025	51%	2.73%	3.56%	42.74%
Sep 2025	51%	2.41%	3.51%	43.08%
Dec 2025	51%	2.72%	0.82%	45.43%
Mar 2026	51%	2.43%	0.87%	45.69%
Jun 2026	51%	2.77%	0.59%	45.65%
Sep 2026	51%	2.39%	1.77%	44.83%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Other Assets	Total Assets
Mar 2015	92	103	50	196	442	286	3	153	442
Mar 2016	92	132	52	185	460	301	3	157	460
Mar 2017	92	139	67	160	458	296	0	163	458
Mar 2018	92	141	66	134	432	294	0	138	432
Mar 2019	92	152	21	157	422	280	1	141	422
Mar 2020	92	176	4	177	449	303	0	146	449
Mar 2021	92	181	3	157	432	283	3	145	432
Mar 2022	92	234	5	131	462	277	0	185	462
Mar 2023	92	288	2	173	555	275	3	278	555
Mar 2024	92	386	34	212	723	347	0	376	723
Mar 2025	92	505	33	222	852	328	33	491	852
Mar 2026	92	649	37	214	991	365	3	624	991

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	64	-29	-35	0
Mar 2016	62	-33	-30	0
Mar 2017	28	-22	-5	0
Mar 2018	48	-30	-17	1
Mar 2019	75	-17	-44	14
Mar 2020	86	-40	-43	4
Mar 2021	27	-19	-3	5
Mar 2022	94	-74	-3	17
Mar 2023	144	-108	-26	11
Mar 2024	200	-158	-32	9
Mar 2025	157	-111	-46	0
Mar 2026	167	-178	-46	-57

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	40	41	47	41	35	35	40	18	23	17	20	28
Inventory Days	—	—	—	—	—	—	—	—	—	—	—	—
Days Payable	—	—	—	—	—	—	—	—	—	—	—	—
Cash Conversion Cycle	40	41	47	41	35	35	40	18	23	17	20	28
Working Capital Days	-35	-22	-17	-7	-5	-10	-1	-2	-12	-24	-19	-4
ROCE %	23%	18%	17%	15%	19%	21%	3%	29%	34%	38%	39%	36%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of INDRAPRASTHA MEDICAL CORP (INDRAMEDCO)?

The reported market capitalisation for INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) is ₹2,934Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of INDRAMEDCO?

The current price shown for INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) on Fincrux is ₹320 with a 52-week high/low of ₹641/317.

What is the P/E ratio of INDRAPRASTHA MEDICAL CORP (INDRAMEDCO)?

The stock P/E for INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) is 15.6 on Fincrux, with ROE at 27.4% and ROCE at 35.8%.

What were INDRAMEDCO latest quarterly results?

For Jun 2026, INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) reported sales ₹406 Cr and net profit ₹56 Cr (figures in ₹ crore unless noted).

What are INDRAMEDCO annual sales and net profit?

For TTM, INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) shows sales of ₹1,524 Cr and net profit of ₹188 Cr on the Fincrux profit & loss statement.

Who owns INDRAPRASTHA MEDICAL CORP (INDRAMEDCO)?

Latest shareholding for INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) on Fincrux: Promoters 51.00% (Sep 2026), FIIs 2.39% (Sep 2026), DIIs 1.77% (Sep 2026), Public 44.83% (Sep 2026), No. of Shareholders 77,706% (Sep 2026).

Where can I find INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) financials?

INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show INDRAMEDCO balance sheet and cash flow?

Yes. The INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 2:57